Current Report Filing (8-k)
08 April 2017 - 4:33AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported):
April 7,
2017
NORTHWEST BIOTHERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-35737
|
94-3306718
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
4800 Montgomery Lane, Suite
800
Bethesda, MD 20814
|
(Address of principal executive offices)
|
(204) 497-9024
|
(Registrant’s telephone number, including area code)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Northwest Biotherapeutics,
Inc. (the “Company”) has received shareholder inquiries asking for re-confirmatio
n
that the partial hold on screening for enrollment in the Company’s Phase III trial was lifted as described in the Company’s
prior announcement on February 6, 2017, as the Company’s most recent Prospectus Supplement did not contain this update.
The Company re-confirmed that the FDA’s partial hold was lifted as previously reported.
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE
SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO
DULY AUTHORIZED.
|
NORTHWEST BIOTHERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
|
Date: April 7, 2017
|
By:
|
/s/
Linda F. Powers
|
|
|
Name: Linda F. Powers
Title: Chief Executive Officer
|
|
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Apr 2024 to May 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From May 2023 to May 2024